Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Gynecologic 3Tumor-Agnostic 2Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Sarcoma 1Head & Neck 1Endocrine 1CNS 1Breast 1

Conditions

HRD Cancer 1Advanced Solid Tumor 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
berzosertib × Other solid neoplasm × Clear all
NCT04826341 2026-05-29

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
35 enrolled
Other solid neoplasmThoracic

HRD Cancer

NCT02157792 2020-04-01

M6620 First in Human Study

EMD Serono

Phase 1 Completed
200 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡